RxDoctor Payments DataLook up a doctor →

Eric Adler, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1477699601

Payments from drug & device makers

$1,361,816in general payments, 2019–2025

Across 261 payments — averaging $5217.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$553K
  • E.r. Squibb & Sons, L.L.C.$356K
  • Abbott$233K
  • Medtronic$88K
  • Pfizer$65K
  • Livanova USA, Inc.$24K
  • plus $44K from 20 others
$1,270in research payments, 2019–2025

Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1K

What the payments were for

  • Consulting fees$5,06922%
  • Speaking & faculty fees$6,30027%
  • Travel & lodging$4,45719%
  • Food & beverage$7,66833%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,361,816 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$44,862
Medicare patients
152
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine34$713,476
VyndamaxTafamidis25$544,688
CamzyosMavacamten13$109,903
JardianceEmpagliflozin112$106,913
EntrestoSacubitril/Valsartan80$91,427
FarxigaDapagliflozin Propanediol39$39,390
EliquisApixaban30$25,786
XareltoRivaroxaban11$16,186
CorlanorIvabradine Hcl26$14,626
Eplerenone23$2,170
Bumetanide32$1,441
Metoprolol Succinate57$830
Potassium Chloride37$717
Atorvastatin Calcium40$712
Carvedilol58$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Vyndamax, Eliquis$64,865$1,283,94989 claims
E.r. Squibb & Sons, L.L.C.Camzyos$356,113$109,90313 claims
NovartisEntresto$3,414$91,42780 claims
AstraZenecaFarxiga$21$39,39039 claims
Johnson & JohnsonXarelto$19$16,18611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →